Microscopic Polyangiitis Clinical Trial
— MONITUXOfficial title:
Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)
Verified date | November 2020 |
Source | Centre Hospitalier Universitaire de Saint Etienne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels could be an interesting tool in the follow-up of ANCA-associated vasculitis patients. All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or the relapse of a known ANCA-associated vasculitis, in which the decision to start an induction regimen with rituximab has been taken, will be included. Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.
Status | Terminated |
Enrollment | 28 |
Est. completion date | June 12, 2020 |
Est. primary completion date | June 12, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age > 18 years - Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill criterions), with or without detectable ANCA - Decision taken to start an induction regimen with rituximab - Informed and having signed the study consent form - If of child-bearing potential, female patients will have use an effective method of contraception during RTX (rituximab) treatment and in the 12 months following RTX treatment stop - no-breast-feeding during RTX treatment and in the 12 months following RTX treatment stop Exclusion Criteria: - Other primary or secondary systemic vasculitis - Incapacity or refusal to sign the informed consent form - Incapacity or refusal to adhere to treatment or perform the follow-up examinations required by the study - Allergy, documented hypersensitivity or contraindication to the medications used in the present study (corticosteroids, rituximab) - severe active infection - Patient with severe heart failure (stage NYHA IV) or any other unstable heart disease Pregnancy, except for cases where the expected benefit oj treatment seems to surpass the potential risks - Patients with active hepatitis B - Any live vaccine within four weeks prior to the first infusion of RTX |
Country | Name | City | State |
---|---|---|---|
France | Hôpital de la Croix Rousse | Lyon | |
France | Hôpital Edouard Herriot | Lyon | |
France | CH Lyon Sud | Pierre-Bénite | |
France | CHU Saint-Etienne | Saint-Etienne |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Saint Etienne | Theradiag |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | serum rituximab levels | rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0, 6 months after stop of induction regimen | 1 month after stop of rituximab induction regimen | |
Secondary | serum rituximab levels | rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 3 months after stop of rituximab induction regimen | |
Secondary | serum rituximab levels | rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 6 months after stop of rituximab induction regimen | |
Secondary | serum anti-rituximab antibodies | serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 1 month after stop of rituximab induction regimen | |
Secondary | serum anti-rituximab antibodies | serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 3 months after stop of rituximab induction regimen | |
Secondary | serum anti-rituximab antibodies | serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 6 months after stop of rituximab induction regimen | |
Secondary | Serum B lymphocytes (CD19+ cells) levels | Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 1 month after stop of rituximab induction regimen | |
Secondary | Serum B lymphocytes (CD19+ cells) levels | Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 3 months after stop of rituximab induction regimen | |
Secondary | Serum B lymphocytes (CD19+ cells) levels | Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score > 0 six months after stop of induction regimen | 6 months after stop of rituximab induction regimen | |
Secondary | patient number with adverse event | frequency and nature of rituximab-attributed adverse events | from start of induction rituximab regimen until six monthes after stop of induction regimen |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01729624 -
PRO Development for ANCA Associated Vasculitis
|
N/A | |
Active, not recruiting |
NCT02198248 -
Low-dose Glucocorticoid Vasculitis Induction Study
|
Phase 4 | |
Completed |
NCT02190916 -
Vasculitis Illness Perception (VIP) Study
|
N/A | |
Recruiting |
NCT01241305 -
One-Time DNA Study for Vasculitis
|
||
Completed |
NCT00748644 -
Efficacy Study of Two Treatments in the Remission of Vasculitis
|
Phase 3 | |
Recruiting |
NCT02967068 -
VCRC Tissue Repository
|
||
Completed |
NCT01731561 -
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
|
Phase 3 | |
Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Completed |
NCT02190942 -
VCRC Patient Contact Registry Patient-Reported Data Validation Study
|
||
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Terminated |
NCT01586858 -
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
|
N/A | |
Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
Completed |
NCT02190929 -
Educational Needs of Patients With Systemic Vasculitis
|
N/A | |
Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
Completed |
NCT02476292 -
Impact of Vasculitis on Employment and Income
|
N/A | |
Completed |
NCT02169219 -
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
|
Phase 4 | |
Completed |
NCT01613599 -
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
||
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 |